2 years ago-Biopharma Group

Building a Patient-centric CGT Supply Chain

Views: 39

As more cell and gene therapies (CGT) move toward commercial production, biopharmaceutical innovators developing these potentially life-saving treatments will need reliable, fast, and efficient technologies for seamless collection, processing, and delivery. This article by Dr. Minh Hong, Mark Sawicki and Gabriela Hertz-Bruno at Lonza will examine supply chain best practices to ensure the effective manufacturing and delivery of CGTs to the patients who need them the most.

Comments: 0

Your email address will not be published. Required fields are marked with *


Your Cart